Although pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARα) agonist, has demonstrated significant benefits in improving lipid profiles in several clinical trials, its long-term effects and safety, particularly in diabetic and kidney disease patients, remain controversial. This evidence concerns the gene PPARA and kidney disorder.